 |
|
|
| |
Extrapolating Expected Efficacy, Safety, and Pharmacokinetics (PK) of Dolutegravir/Lamivudine (DTG/3TC) in
Pregnant People Living With HIV-1 From Pregnancy Data With Combination DTG and/or 3TC Antiretroviral Therapies
|
| |
| |
IDWeek 2024; October 16-19, 2024; Los Angeles, CA
William R. Short,1 Parul Patel,2 Gustavo Verdier,3 Ana Puga,2 Andrew Weber,2 Leigh Ragone,2 Eva Fernvik,4 Vani Vannappagari,2 V. Paul DiMondi,2 Bryn Jones5
1Department of Medicine, Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 2ViiV Healthcare, Durham, NC, USA; 3ViiV Healthcare, Montréal, Canada; 4ViiV Healthcare, Stockholm, Sweden; 5ViiV Healthcare, Brentford, UK
|
| |
|
|
|
|
|
